New review article highlights Nevisense effectiveness in identifying malignant skin lesions

The overarching goal of the review is to summarize the clinical potential of state-of-the-art impedance-based technologies, explaining distinct electrical signatures inherent to cancer vs healthy tissues. These techniques offer real-time insights into tumor dynamics, paving the way for precision-guided therapeutic interventions. The overarching goal of the review is to summarize the clinical potential of state-of-the-art impedance-based technologies, explaining distinct electrical signatures...
Comunicato Precedente

next
Comunicato Successivo

next
STOCKHOLM, (informazione.it - comunicati stampa - salute e benessere)

The overarching goal of the review is to summarize the clinical potential of state-of-the-art impedance-based technologies, explaining distinct electrical signatures inherent to cancer vs healthy tissues. These techniques offer real-time insights into tumor dynamics, paving the way for precision-guided therapeutic interventions.

The article is available through the following link: https://doi.org/10.1002/bem.22540

"This is an interesting review of important technologies for identifying different cancers. Nevisense represents an innovative approach to enhancing early-stage melanoma detection while minimizing unnecessary medical procedures through real-time impedance measurements," says Pia Renaudin, CEO of SciBase.

For additional information, please contact:
Pia Renaudin, CEO, tel. +46732069802, e-mail: pia.renaudin@scibase.com

Certified Advisor (CA):
Carnegie Investment Bank AB (publ)
Phone: +46 (0)73 856 42 65
E-mail: certifiedadviser@carnegie.se

About SciBase

SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to enhance diagnostic accuracy, ensuring proactive skin health management. 

Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.

Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.

The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015, and the company's Certified Adviser is Carnegie Investment Bank AB (publ). Learn more at www.scibase.com.

For press releases and financial reports visit: http://investors.scibase.se/en/pressreleases 

This information was brought to you by Cision http://news.cision.com.

https://news.cision.com/scibase/r/new-review-article-highlights-nevisense-effectiveness-in-identifying-malignant-skin-lesions,c4096664

The following files are available for download:

 

Cision View original content:https://www.prnewswire.co.uk/news-releases/new-review-article-highlights-nevisense-effectiveness-in-identifying-malignant-skin-lesions-302361630.html

Ufficio Stampa

 PR Newswire (Leggi tutti i comunicati)
209 - 215 Blackfriars Road
LONDON United Kingdom

Allegati
Non disponibili